Isracann Biosciences EBITDA vs. Shares Outstanding

Based on Isracann Biosciences' profitability indicators, Isracann Biosciences may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Isracann Biosciences' ability to earn profits and add value for shareholders.
For Isracann Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Isracann Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Isracann Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Isracann Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Isracann Biosciences over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis.
Please note, there is a significant difference between Isracann Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Isracann Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Isracann Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Isracann Biosciences Shares Outstanding vs. EBITDA Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Isracann Biosciences's current stock value. Our valuation model uses many indicators to compare Isracann Biosciences value to that of its competitors to determine the firm's financial worth.
Isracann Biosciences is rated second overall in ebitda category among its peers. It is rated fifth overall in shares outstanding category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Isracann Biosciences' earnings, one of the primary drivers of an investment's value.

Isracann Shares Outstanding vs. EBITDA

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Isracann Biosciences

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(4.64 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Isracann Biosciences

Shares Outstanding

 = 

Public Shares

-

Repurchased

 = 
175.99 M
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.

Isracann Shares Outstanding Comparison

Isracann Biosciences is currently under evaluation in shares outstanding category among its peers.

Isracann Biosciences Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Isracann Biosciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Isracann Biosciences will eventually generate negative long term returns. The profitability progress is the general direction of Isracann Biosciences' change in net profit over the period of time. It can combine multiple indicators of Isracann Biosciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Isracann Biosciences Inc., together with its subsidiaries, cultivates and distributes medical cannabis in Israel. Isracann Biosciences Inc. was founded in 2010 and is headquartered in Vancouver, Canada. Isracann Biosciences is traded on OTC Exchange in the United States.

Isracann Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Isracann Biosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Isracann Biosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Isracann Biosciences' important profitability drivers and their relationship over time.

Use Isracann Biosciences in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Isracann Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Isracann Biosciences will appreciate offsetting losses from the drop in the long position's value.

Isracann Biosciences Pair Trading

Isracann Biosciences Pair Trading Analysis

The ability to find closely correlated positions to Isracann Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Isracann Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Isracann Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Isracann Biosciences to buy it.
The correlation of Isracann Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Isracann Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Isracann Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Isracann Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Isracann Biosciences position

In addition to having Isracann Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Software Thematic Idea Now

Software
Software Theme
Companies that develop and distribute software and software systems to individuals or business. The Software theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Software Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Isracann Pink Sheet

To fully project Isracann Biosciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Isracann Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Isracann Biosciences' income statement, its balance sheet, and the statement of cash flows.
Potential Isracann Biosciences investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Isracann Biosciences investors may work on each financial statement separately, they are all related. The changes in Isracann Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Isracann Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.